Includes LZH spin-offs Rowiak GmbH and neoLase GmbH.
: Some estimates from within the patient community suggest commercial availability may still be roughly 10 years away , as medical research and safety certifications take significant time. xfloater project
. These lasers operate at significantly lower energy levels (microjoules vs. millijoules) and shorter pulse lengths than standard YAG lasers. Expanding Safety Zones: Includes LZH spin-offs Rowiak GmbH and neoLase GmbH
Standard laser treatment for floaters, known as , uses nanosecond pulses to vaporize debris. While effective for some, this method introduces significant energy into the eye, which can lead to complications like cataracts or glaucoma if used too close to the lens or retina. These lasers operate at significantly lower energy levels
: "XFloater – Development of a safer laser-based treatment for vitreous opacities".
(placing availability potentially around 2030) before the technology receives CE certification and is ready for clinical application. Alternatives and Related Research
: While the project has successfully proven the efficiency of the laser system in laboratory settings, it is not yet ready for human trials. The goal is to provide the foundational data necessary for medical device companies to develop commercial treatment systems, with some estimates suggesting a viable treatment could emerge by 2030 .